Company: BWAY
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001171843-25-002347
Chunk: 190

Company: Brainsway Ltd.
Filing Date: 2025-04-22
Form: 20-F
Item: Item 16A
Chunk 190
---
16D. EXEMPTIONS FROM THE
LISTING STANDARDS FOR AUDIT COMMITTEES

Not applicable.

ITEM 16E. PURCHASES OF EQUITY
SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

Not applicable.

ITEM 16F. CHANGE IN REGISTRANT’ S
CERTIFYING ACCOUNTANT

Not applicable.

ITEM 16G. CORPORATE GOVERNANCE

Nasdaq Stock
Listing Rules and Home Country Practices

As a foreign private issuer whose ADSs are listed
on The Nasdaq Global Market, we are permitted to follow certain home country corporate governance practices instead of certain requirements
of the rules of The Nasdaq Global Market. Pursuant to the “foreign private issuer exemption”:

  we established a quorum requirement such that the quorum for any meeting of shareholders                                                   

  150  

  we also follow Israeli corporate governance practice in lieu of Nasdaq Marketplace Rule                                                           
  5635(c), which requires shareholder approval for certain dilutive events (such as issuances that will result in a change of control, certain      
  transactions other than a public offering involving issuances of a 20% or greater interest in us and certain acquisitions of the shares           
  or assets of another company) and prior to an issuance of securities when a stock option or purchase plan is to be established or materially      
  amended or other equity compensation arrangement made or materially amended, pursuant to which stock may be acquired by officers, directors,      
  employees or consultants. By contrast, under the Israeli Companies Law, shareholder approval is required (subject to certain limited exceptions)  
  for, among other things: (a) transactions with directors concerning the terms of their service (including indemnification, exemption,             
  and insurance for their service or for any other position that they may hold at a company); (b) extraordinary transactions with controlling       
  shareholders of publicly held companies; (c) terms of office, and employment or other engagement of our controlling shareholder, if any,          
  or such controlling shareholder’s relative; (d) transactions with the company’s Chief Executive Officer with respect to his                       
  or her compensation, whether in accordance with the approved compensation policy of the company or not, or transactions with officers             
  of the company not in accordance with the approved compensation policy; (e) the compensation policy of the company for office holders;            
  and (f) certain private placements involving the issuance of 20% or more of our total